774 results on '"Locatelli F. (ORCID:0000-0002-7976-3654)"'
Search Results
2. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
- Author
-
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., Zinzani, P. L., Mantegazza, R., Tagliavini, F., Lupo-Stanghellini, M. T., Ciceri, F., Damian, S., Uccelli, A., Fenoglio, D., Silvestris, N., Baldanti, F., Piaggio, G., Ciliberto, G., Morrone, A., Locatelli, Franco, Sinno, V., Rescigno, M., Costantini, M., Locatelli F. (ORCID:0000-0002-7976-3654), Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., Zinzani, P. L., Mantegazza, R., Tagliavini, F., Lupo-Stanghellini, M. T., Ciceri, F., Damian, S., Uccelli, A., Fenoglio, D., Silvestris, N., Baldanti, F., Piaggio, G., Ciliberto, G., Morrone, A., Locatelli, Franco, Sinno, V., Rescigno, M., Costantini, M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
BACKGROUND: Patients with solid or hematological tumors or neurological and immune-inflammatory disorders are potentially fragile subjects at increased risk of experiencing severe coronavirus disease 2019 and an inadequate response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. METHODS: We designed a prospective Italian multicenter study to assess humoral and T-cell responses to SARS-CoV-2 vaccination in patients (n = 378) with solid tumors (ST), hematological malignancies (HM), neurological disorders (ND), and immunorheumatological diseases (ID). A group of healthy controls was also included. We analyzed the immunogenicity of the primary vaccination schedule and booster dose. RESULTS: The overall seroconversion rate in patients after 2 doses was 62.1%. Significantly lower rates were observed in HM (52.4%) and ID (51.9%) than in ST (95.6%) and ND (70.7%); a lower median antibody level was detected in HM and ID versus ST and ND (P < .0001). Similar rates of patients with a positive SARS-CoV-2 T-cell response were found in all disease groups, with a higher level observed in ND. The booster dose improved the humoral response in all disease groups, although to a lesser extent in HM patients, whereas the T-cell response increased similarly in all groups. In the multivariable logistic model, independent predictors of seroconversion were disease subgroup, treatment type, and age. Ongoing treatment known to affect the immune system was associated with the worst humoral response to vaccination (P < .0001) but had no effect on T-cell responses. CONCLUSIONS: Immunosuppressive treatment more than disease type per se is a risk factor for a low humoral response after vaccination. The booster dose can improve both humoral and T-cell responses.
- Published
- 2023
3. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
- Author
-
Locatelli, Franco, Zugmaier, G., Rizzari, C., Morris, J. D., Gruhn, B., Klingebiel, T., Parasole, R., Linderkamp, C., Flotho, C., Petit, A., Micalizzi, C., Zeng, Y., Desai, R., Kormany, W. N., Eckert, C., Moricke, A., Sartor, M., Hrusak, O., Peters, C., Saha, V., Vinti, L., von Stackelberg, A., Locatelli F. (ORCID:0000-0002-7976-3654), Locatelli, Franco, Zugmaier, G., Rizzari, C., Morris, J. D., Gruhn, B., Klingebiel, T., Parasole, R., Linderkamp, C., Flotho, C., Petit, A., Micalizzi, C., Zeng, Y., Desai, R., Kormany, W. N., Eckert, C., Moricke, A., Sartor, M., Hrusak, O., Peters, C., Saha, V., Vinti, L., von Stackelberg, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NO ABSTRACT
- Published
- 2023
4. Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: An I-BFM Study Group collaboration
- Author
-
Hammer, A. S. B., Juul-Dam, K. L., Sandahl, J. D., Abrahamsson, J., Czogala, M., Delabesse, E., Haltrich, I., Jahnukainen, K., Kolb, E. A., Kovacs, G., Leverger, G., Locatelli, Franco, Masetti, R., Noren-Nystro, U., Raimondi, S. C., Rasche, M., Reinhardt, D., Taki, T., Tomizawa, D., Zeller, B., Hasle, H., Kjeldsen, E., Locatelli F. (ORCID:0000-0002-7976-3654), Hammer, A. S. B., Juul-Dam, K. L., Sandahl, J. D., Abrahamsson, J., Czogala, M., Delabesse, E., Haltrich, I., Jahnukainen, K., Kolb, E. A., Kovacs, G., Leverger, G., Locatelli, Franco, Masetti, R., Noren-Nystro, U., Raimondi, S. C., Rasche, M., Reinhardt, D., Taki, T., Tomizawa, D., Zeller, B., Hasle, H., Kjeldsen, E., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic leukemia. We aimed to characterize and study the prognostic impact of hypodiploidy in pediatric AML. In this retrospective cohort study, we included children below 18 years of age with de novo AML and a hypodiploid karyotype diagnosed from 2000 to 2015 in 14 childhood AML groups from the International Berlin-Frankfurt-Münster (I-BFM) framework. Exclusion criteria comprised constitutional hypodiploidy, monosomy 7, composite karyotype, and t(8;21) with concurring sex chromosome loss. Hypodiploidy occurred in 81 patients (1.3%) with MNs, 45 (n = 66); 44 (n = 10) and 43 (n = 5). The most frequently lost chromosomes were chromosome 9 and sex chromosomes. Five-year event-free survival (EFS) and overall survival (OS) were 34% and 52%, respectively, for the hypodiploid cohort. Children with MN≤44 (n = 15) had inferior EFS (21%) and OS (33%) compared with children with MN = 45 (n = 66; EFS, 37%; OS, 56%). Adjusted hazard ratios (HRs) were 4.9 (P = .001) and 6.1 (P = .003). Monosomal karyotype or monosomy 9 had particular poor OS (43% and 15%, respectively). Allogeneic stem cell transplantation (SCT) in first complete remission (CR1) (n = 18) did not mitigate the unfavorable outcome of hypodiploidy (adjusted HR for OS was 1.5; P = .42). We identified pediatric hypodiploid AML as a rare subgroup with an inferior prognosis even in the patients treated with SCT in CR1.
- Published
- 2023
5. First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis
- Author
-
Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
We describe the first case of bridge therapy in alpha-mannosidosis (AM) in an infant diagnosed at only 5 months of life who underwent enzyme replacement therapy (ERT) in the pre- and peri-transplant phases. Eight ERT infusions were administered before hematopoietic stem cell transplantation (HSCT) and continued for additional 90 days until complete engraftment. The clinical and laboratory data after 3 years post-HSCT show that the early combined intervention may reduce the disease progression and the urine and plasma content of mannosyl-oligosaccharides (OS) monitored by liquid chromatography tandem mass spectrometry (LC–MS/MS). This report highlights that early diagnosis and prompt initiation of such treatments in AM are the best chance to minimize the progression of symptoms.
- Published
- 2023
6. Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor
- Author
-
Algeri, M., Velardi, E., Spada, M., Galaverna, F., Carta, R., Vinti, L., Palumbo, G., Gaspari, S., Pietrobattista, A., Boccieri, E., Becilli, M., Francalanci, P., Bertaina, V., Merli, P., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Algeri, M., Velardi, E., Spada, M., Galaverna, F., Carta, R., Vinti, L., Palumbo, G., Gaspari, S., Pietrobattista, A., Boccieri, E., Becilli, M., Francalanci, P., Bertaina, V., Merli, P., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hematopoietic stem cell transplantation (HSCT)–based approaches are increasingly investigated strategies to induce tolerance in recipients of solid allografts. However, in the majority of cases, these approaches rely on the infusion of hematopoietic stem cells recovered from the same solid organ donor. In this report, we describe the case of a boy who received liver transplantation from a deceased donor, who had successfully underwent allogeneic HSCT from an unrelated donor for hepatitis-associated aplastic anemia. In this patient, it was possible to permanently withdraw post-HSCT immune suppression without causing any sign of liver graft dysfunction. To the best of our knowledge, this is the first case of operational tolerance documented in a patient who received combined liver transplantation and HSCT from different donors.
- Published
- 2023
7. Pediatric BCOR-Altered Tumors From Soft Tissue/Kidney Display Specific DNA Methylation Profiles
- Author
-
Salgado, C. M., Alaggio, R., Ciolfi, A., Zin, A., Diomedi Camassei, F., Pedace, L., Milano, G. M., Serra, A., Di Giannatale, A., Mastronuzzi, A., Gianatti, A., Bisogno, G., Ferrari, A., Tartaglia, M., Reyes-Mugica, M., Locatelli, Franco, Miele, E., Locatelli F. (ORCID:0000-0002-7976-3654), Salgado, C. M., Alaggio, R., Ciolfi, A., Zin, A., Diomedi Camassei, F., Pedace, L., Milano, G. M., Serra, A., Di Giannatale, A., Mastronuzzi, A., Gianatti, A., Bisogno, G., Ferrari, A., Tartaglia, M., Reyes-Mugica, M., Locatelli, Franco, Miele, E., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
In the pediatric population, BCL6-correpresor gene (BCOR)-upregulated tumors include primitive myxoid mesenchymal tumors/undifferentiated sarcomas (PMMTI/UND), clear cell sarcomas of the kidney (CCSK), and high-grade neuroepithelial tumors (HG-NET). We investigated DNA methylation (DNAm) and copy number variation (CNV) profiling in these tumors (N = 34) using an Illumina EPIC BeadChip to better define the potential use of these tools to confirm diagnosis and predict outcomes. Twenty-seven tumors from 25 patients (age range, 0-10 years), showed molecular confirmation of genetic abnormalities as follows: BCOR internal tandem duplication in 14 PMMTI/UND, 8 CCSK, and 3 HG-NET and YWHAE fusions in 2 PMMTI/UND. The remaining 7 cases lacking informative molecular data were analyzed by immunophenotyping and were included in the study as a training cohort, clearly separated from the main study group. These were 4 PMMTI, 1 HG-NET, and 1 CCSK in which poor RNA preservation precluded the confirmation of BCOR rearrangements and 1 CCSK in which no rearrangements were found. DNAm data were compared with those of brain tumor and/or sarcoma classifier. Differentially methylated regions (DMRs) were analyzed in the 3 groups. Twenty-two cases of the 24 molecularly confirmed PMMTI/UND and CCSK and 3 of 6 of those with only immunophenotyping were classified within the methylation class "BCOR-altered sarcoma family" with optimal calibrated scores. PMMTI/UND and CCSK showed similar methylation profiles, whereas thousands of DMRs and significantly enriched pathways were evident between soft tissue/kidney tumors and HG-NET. The CNV analysis showed an overall flat profile in 19 of the 31 evaluable tumors (8/10 CCSK; 9/18 PMMTI/UND; 2/4 HG-NET). The most frequent CNVs were 1q gain and 9p and 10q loss. Follow-up time data were available for 20 patients: ≥2 CNV significantly correlated with a worse overall survival rate. In conclusion, soft tissue and kidney BCOR sarcomas matched with BCOR
- Published
- 2023
8. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft
- Author
-
Vinci, L., Flotho, C., Noellke, P., Lebrecht, D., Masetti, R., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Gungor, T., Stary, J., Turkiewicz, D., Ussowicz, M., de Heredia, C. D., Buechner, J., Jahnukainen, K., Kallay, K., Bodova, I., Smith, O. P., Zecca, M., Bresters, D., Lang, P., Masmas, T. N., Meisel, R., Pichler, H., Erlacher, M., Gohring, G., Locatelli, Franco, Strahm, B., Niemeyer, C. M., Yoshimi, A., Locatelli F. (ORCID:0000-0002-7976-3654), Vinci, L., Flotho, C., Noellke, P., Lebrecht, D., Masetti, R., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Gungor, T., Stary, J., Turkiewicz, D., Ussowicz, M., de Heredia, C. D., Buechner, J., Jahnukainen, K., Kallay, K., Bodova, I., Smith, O. P., Zecca, M., Bresters, D., Lang, P., Masmas, T. N., Meisel, R., Pichler, H., Erlacher, M., Gohring, G., Locatelli, Franco, Strahm, B., Niemeyer, C. M., Yoshimi, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NO ABSTRACT
- Published
- 2023
9. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia
- Author
-
Scutari, R., Fox, V., De Ioris, M. A., Fini, V., Granaglia, A., Costabile, V., Colagrossi, L., Russo, C., Mastronuzzi, A., Locatelli, Franco, Perno, C. F., Alteri, C., Locatelli F. (ORCID:0000-0002-7976-3654), Scutari, R., Fox, V., De Ioris, M. A., Fini, V., Granaglia, A., Costabile, V., Colagrossi, L., Russo, C., Mastronuzzi, A., Locatelli, Franco, Perno, C. F., Alteri, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Since its emergence in November 2021, SARS-CoV-2 Omicron clade has quickly become dominant, due to its increased transmissibility and immune evasion. Different sublineages are currently circulating, which differ in mutations and deletions in regions of the SARS-CoV-2 genome implicated in the immune response. In May 2022, BA.1 and BA.2 were the most prevalent sublineages in Europe, both characterized by ability of evading natural acquired and vaccine-induced immunity and of escaping monoclonal antibodies neutralization. Case presentation: A 5-years old male affected by B-cell acute lymphoblastic leukemia in reinduction was tested positive for SARS-CoV-2 by RT-PCR at the Bambino Gesù Children Hospital in Rome in December 2021. He experienced a mild COVID-19 manifestation, and a peak of nasopharyngeal viral load corresponding to 15.5 Ct. Whole genome sequencing identified the clade 21 K (Omicron), sublineage BA.1.1. The patient was monitored over time and tested negative for SARS-CoV-2 after 30 days. Anti-S antibodies were detected positive with modest titre (3.86 BAU/mL), while anti-N antibodies were negative. 74 days after the onset of the first infection and 23 days after the last negative test, the patient was readmitted to hospital with fever, and tested positive for SARS-CoV-2 by RT-PCR (peak of viral load corresponding to 23.3 Ct). Again, he experienced a mild COVID-19. Whole genome sequencing revealed an infection with the Omicron lineage BA.2 (21L clade). Sotrovimab administration was started at the fifth day of positivity, and RT-PCR negativity occurred 10 days later. Surveillance SARS-CoV-2 RT-PCR were persistently negative, and in May 2022, anti-N antibodies were found positive and anti-S antibodies reached titres > 5000 BAU/mL. Conclusions: By this clinical case, we showed that SARS-CoV-2 reinfection within the Omicron clade can occur and can be correlated to inadequate immune responses to primary infection. We also
- Published
- 2023
10. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
- Author
-
Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., Locatelli F. (ORCID:0000-0002-7976-3654), Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NO ABSTRACT
- Published
- 2023
11. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
- Author
-
Ceolin, V., Brivio, E., van Tinteren, H., Rheingold, S. R., Leahy, A., Vormoor, B., O'Brien, M. M., Rubinstein, J. D., Kalwak, K., De Moerloose, B., Jacoby, E., Bader, P., Lopez-Duarte, M., Goemans, B. F., Locatelli, Franco, Hoogerbrugge, P., Calkoen, F. G., Zwaan, C. M., Locatelli F. (ORCID:0000-0002-7976-3654), Ceolin, V., Brivio, E., van Tinteren, H., Rheingold, S. R., Leahy, A., Vormoor, B., O'Brien, M. M., Rubinstein, J. D., Kalwak, K., De Moerloose, B., Jacoby, E., Bader, P., Lopez-Duarte, M., Goemans, B. F., Locatelli, Franco, Hoogerbrugge, P., Calkoen, F. G., Zwaan, C. M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Chimeric antigen receptor T cells targeting CD19 (CART-19) have shown remarkable efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We investigated whether prior use of inotuzumab ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, may impact CAR T-cell manufacturing or efficacy via pre-CART-19 depletion of the B-cell compartment. In this international, retrospective analysis, 39 children and young adults receiving InO before (n = 12) and/or after (n = 27) T-cell apheresis as bridging therapy to CART-19 treatment were analyzed. Median age at infusion was 13 years (range 1.4–23 years). Thirty-four out of 39 patients (87.2%) obtained complete remission. With a median follow-up of 18.2 months after CART-19 infusion, 12-month event-free survival (EFS) was 53.3% (95% confidence interval (CI): 38.7–73.4) and overall survival (OS) was 77.8% (95% CI: 64.5–93.9). Seventeen patients (44%) relapsed with a median of 159 days (range 28–655) after CART-19 infusion. No difference in day 28 minimal residual disease negative complete response rate, 12-month OS/EFS, or incidence of CD19-positive or -negative relapses was observed among patients receiving InO before or after apheresis. Compared to published data for patients treated with CART-19 therapy without prior InO exposure, response and OS/EFS for patients treated with InO prior to CART-19 are similar.
- Published
- 2023
12. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
- Author
-
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., Li Pira, G., Leone, G., Bertaina, V., Sinibaldi, M., Di Cecca, S., Guercio, M., Abbaszadeh, Z., Iaffaldano, L., Gunetti, M., Iacovelli, S., Bugianesi, R., Macchia, S., Algeri, M., Merli, P., Galaverna, F., Abbas, R., Garganese, M. C., Villani, M. F., Colafati, G. S., Bonetti, F., Rabusin, M., Perruccio, K., Folsi, V., Quintarelli, C., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., Li Pira, G., Leone, G., Bertaina, V., Sinibaldi, M., Di Cecca, S., Guercio, M., Abbaszadeh, Z., Iaffaldano, L., Gunetti, M., Iacovelli, S., Bugianesi, R., Macchia, S., Algeri, M., Merli, P., Galaverna, F., Abbas, R., Garganese, M. C., Villani, M. F., Colafati, G. S., Bonetti, F., Rabusin, M., Perruccio, K., Folsi, V., Quintarelli, C., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. Methods: In an academic, phase 1-2 clinical trial, we enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). Results: A total of 27 children with heavily pretreated neuroblastoma (12 with refractory disease, 14 with relapsed disease, and 1 with a complete response at the end of first-line therapy) were enrolled and received GD2-CART01. No failure to generate GD2-CART01 was observed. Three dose levels were tested (3-, 6-, and 10×106 CAR-positive T cells per kilogram of body weight) in the phase 1 portion of the trial, and no dose-limiting toxic effects were recorded; the recommended dose for the phase 2 portion of the trial was 10×106 CAR-positive T cells per kilogram. Cytokine release syndrome occurred in 20 of 27 patients (74%) and was mild in 19 of 20 (95%). In 1 patient, the suicide gene was activated, with rapid elimination of GD2-CART01. GD2-targeted CAR T cells expanded in vivo and were detectable in peripheral blood in 26 of 27 patients up to 30 months after infusion (median persistence, 3 months; range, 1 to 30). Seventeen children had a response to the treatment (overall response, 63%); 9 patients had a complete response, and 8 had a partial response. Among the patients who received the recommended dose, the 3-year overall survival and event-free survival were 60% and 36%, respectively. Conclusions: The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others
- Published
- 2023
13. Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors
- Author
-
Merli, P., Crivello, P., Strocchio, L., Pinto, R. M., Algeri, M., Del Bufalo, F., Pagliara, D., Becilli, M., Carta, R., Gaspari, S., Galaverna, F., Quagliarella, F., Boz, G., Catanoso, M. L., Boccieri, E., Troiano, M., Fleischhauer, K., Andreani, M., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Merli, P., Crivello, P., Strocchio, L., Pinto, R. M., Algeri, M., Del Bufalo, F., Pagliara, D., Becilli, M., Carta, R., Gaspari, S., Galaverna, F., Quagliarella, F., Boz, G., Catanoso, M. L., Boccieri, E., Troiano, M., Fleischhauer, K., Andreani, M., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
High genetic heterogeneity in the human leukocyte antigen (HLA) increases the likelihood of efficient immune response to pathogens and tumours. As measure of HLA diversity, HLA evolutionary divergence (HED) has been shown to predict the response of tumours to immunotherapy and haematopoietic stem cell transplantation (HSCT) in adults. We retrospectively investigated the association of HED with outcomes of 153 paediatric/young adults patients, treated for malignant disorders with HSCT from 9–10/10 HLA-matched unrelated donors. HED was calculated as pairwise genetic distance between alleles in patient HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, using the locus median to stratify patients with ‘high’ or ‘low’ HED. Patients with high HED-B and -DRB1 showed significantly improved disease-free survival (DFS), especially when combined (70.8% vs 53.7% p = 0.008). High HED-B + -DRB1 was also associated with improved overall survival (OS) (82.1 vs 66.4% p = 0.014), and concomitant reduction of non-relapse-mortality (5.1% vs 21.1% p = 0.006). The impact on OS and DFS of combined HED-B + -DRB1 was confirmed in multivariate analysis [hazard ratio (HR) 0.39, p = 0.009; and HR 0.45, p = 0.007 respectively]. Only high HED scores for HLA-DPB1 were associated, in univariate analysis, with reduced incidence of relapse (15.9% vs 31.1%, p = 0.03). These results support HED as prognostic marker in allogeneic HSCT and, if confirmed in larger cohorts, would allow its use to inform clinical risk and potentially influence clinical practice.
- Published
- 2023
14. Response to: meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data
- Author
-
Masetti, R., Muratore, E., Gori, D., Prete, A., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Masetti, R., Muratore, E., Gori, D., Prete, A., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
N/A
- Published
- 2023
15. Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients
- Author
-
Bordoni, V., Casale, M., Pinto, V. M., Carsetti, R., Gianesin, B., Gamberini, M. R., Mazdai, L., Barella, S., Denotti, A. R., Colavita, F., Perrotta, S., Maggio, A., Pitrolo, L., Quintino, S., Caminati, M., Mazzi, F., Ceolan, J., De Franceschi, L., Forni, G. L., Locatelli, Franco, Agrati, C., Locatelli F. (ORCID:0000-0002-7976-3654), Bordoni, V., Casale, M., Pinto, V. M., Carsetti, R., Gianesin, B., Gamberini, M. R., Mazdai, L., Barella, S., Denotti, A. R., Colavita, F., Perrotta, S., Maggio, A., Pitrolo, L., Quintino, S., Caminati, M., Mazzi, F., Ceolan, J., De Franceschi, L., Forni, G. L., Locatelli, Franco, Agrati, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
N/A
- Published
- 2023
16. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- Author
-
Queudeville, M., Stein, A. S., Locatelli, Franco, Ebinger, M., Handgretinger, R., Gokbuget, N., Gore, L., Zeng, Y., Gokani, P., Zugmaier, G., Kantarjian, H. M., Locatelli F. (ORCID:0000-0002-7976-3654), Queudeville, M., Stein, A. S., Locatelli, Franco, Ebinger, M., Handgretinger, R., Gokbuget, N., Gore, L., Zeng, Y., Gokani, P., Zugmaier, G., Kantarjian, H. M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: A lower baseline bone marrow blast percentage (bBMB%) is associated with better outcomes in patients with B-cell acute lymphoblastic leukemia (B-ALL) receiving blinatumomab. The objective of this analysis was to investigate the association between bBMB% and treatment outcomes in relapsed/refractory (R/R) B-ALL. Methods: Data from five trials of blinatumomab for R/R B-ALL were pooled for analyses. Patients were placed in one of three groups: group 1, ≥50% bBMBs; group 2, ≥25% to <50% bBMBs; group 3, ≥5% to <25% bBMBs. Response and survival outcomes were compared between groups. Results: Data from 683 patients (166 pediatric, 517 adult) were analyzed. Collectively, patients in groups 2 and 3 had significantly higher odds of achieving a complete remission (CR) (odds ratio [OR], 3.50 [95% confidence interval (CI), 2.23–5.48] and 3.93 [95% CI, 2.50–6.18], respectively; p <.001) and minimal/measurable residual disease response (OR, 2.61 and 3.37, respectively; p <.001) when compared with group 1 (reference). Groups 2 and 3 had a 37% and 46% reduction in the risk of death (hazard ratio [HR], 0.63 and 0.54, respectively; p <.001) and a 41% and 43% reduction in the risk of an event (relapse or death) (HR, 0.59 and 0.57, respectively; p <.001) compared with group 1. No significant differences in response or survival outcomes were observed between groups 2 and 3. Seven of nine patients whose bBMB% was lowered to <50% with dexamethasone achieved CR with blinatumomab. Conclusion: Any bBMB% <50% was associated with improved efficacy following blinatumomab treatment for R/R B-ALL.
- Published
- 2023
17. The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children
- Author
-
Ilan, U., Brivio, E., Algeri, M., Balduzzi, A., Gonzalez-Vincent, M., Locatelli, Franco, Zwaan, C. M., Baruchel, A., Lindemans, C., Bautista, F., Locatelli F. (ORCID:0000-0002-7976-3654), Ilan, U., Brivio, E., Algeri, M., Balduzzi, A., Gonzalez-Vincent, M., Locatelli, Franco, Zwaan, C. M., Baruchel, A., Lindemans, C., Bautista, F., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hematopoietic stem cell transplantation (HSCT) is often the only curative treatment option for patients suffering from various types of malignant diseases and some non-cancerous conditions. Nevertheless, it is associated with a high risk of complications leading to transplant-related mortality and long-term morbidity. An increasing number of therapeutic and prevention strategies have been developed over the last few years to tackle the complications arising in patients receiving an HSCT. These strategies have been mainly carried out in adults and some are now being translated into children. In this manuscript, we review the recent advancements in the development and implementation of treatment options for post-HSCT non-infectious complications in pediatric patients with leukemia and other non-malignant conditions, with a special attention on the new agents available within clinical trials. We focused on the following conditions: graft failure, prevention of relapse and early interventions after detection of minimal residual disease positivity following HSCT in acute lymphoblastic and myeloid leukemia, chronic graft versus host disease, non-infectious pulmonary complications, and complications of endothelial origin.
- Published
- 2023
18. Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
- Author
-
Agrati, C., Bartolini, B., Bordoni, V., Locatelli, Franco, Capobianchi, M. R., Di Caro, A., Castilletti, C., Ippolito, G., Locatelli F. (ORCID:0000-0002-7976-3654), Agrati, C., Bartolini, B., Bordoni, V., Locatelli, Franco, Capobianchi, M. R., Di Caro, A., Castilletti, C., Ippolito, G., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The immune response to invading pathogens is characterized by the rapid establishment of a complex network of cellular interactions and soluble signals. The correct balancing of activating and regulating pathways and tissue-homing signals determines its effectiveness and persistence over time. Emerging viral pathogens have always represented a great challenge to the immune system and an often uncontrolled/imbalanced immune response has been described (e.g. cytokine storm, immune paralysis), contributing to the severity of the disease. Several immune biomarkers and cell subsets have been identified as major players in the cascade of events leading to severe diseases, highlighting the rationale for host-directed intervention strategy. There are millions of immunocompromised pediatric and adult patients worldwide (e.g. transplant recipients, hematologic patients, subjects with primary immune-deficiencies), experiencing an impaired immune reactivity, due to diseases and/or to the medical treatments. The reduced immune reactivity could have two paradoxical non-exclusive effects: a weak protective immunity on one hand, and a reduced contribution to immune-mediated pathogenetic processes on the other hand. In these sensitive contexts, the impact of emerging infections represents a still open issue to be explored with several challenges for immunologists, virologists, physicians and epidemiologists. In this review, we will address emerging infections in immunocompromised hosts, to summarize the available data concerning the immune response profile, its influence on the clinical presentation, the possible contribution of persistent viral shedding in generating new viral variants with improved immune escape features, and the key role of vaccination.
- Published
- 2023
19. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial
- Author
-
Grupp, S. A., Corbacioglu, S., Kang, H. J., Teshima, T., Khaw, S. L., Locatelli, Franco, Maertens, J., Stelljes, M., Stepensky, P., Lopez, P., Amber, V., Pagliuca, A., Richardson, P. G., Mohty, M., Locatelli F. (ORCID:0000-0002-7976-3654), Grupp, S. A., Corbacioglu, S., Kang, H. J., Teshima, T., Khaw, S. L., Locatelli, Franco, Maertens, J., Stelljes, M., Stepensky, P., Lopez, P., Amber, V., Pagliuca, A., Richardson, P. G., Mohty, M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Sinusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatening complication of haematopoietic stem-cell transplantation (HSCT). We aimed to compare defibrotide prophylaxis plus best supportive care versus best supportive care alone for sinusoidal obstruction syndrome prevention after HSCT. Methods: This open-label, randomised, multicentre, phase 3 trial was done in 104 centres in 14 countries. Patients who were at least 1 month old, were scheduled to receive allogeneic HSCT (adult [aged >16 years] or paediatric [aged >1 month to ≤16 years] patients) or autologous HSCT (paediatric patients only), and were at high risk or very high risk of developing sinusoidal obstruction syndrome were eligible for inclusion. Patients were randomly assigned (1:1) by an interactive web response system to receive intravenous defibrotide 25 mg/kg per day (four equal doses [6·25 mg/kg per dose]) and best supportive care (determined by individual institutional guidelines; defibrotide prophylaxis group) or best supportive care only (best supportive care group). Randomisation was stratified by sinusoidal obstruction syndrome risk, age, and country. The primary endpoint, sinusoidal obstruction syndrome-free survival at day 30 after HSCT, was assessed by an independent Endpoint Adjudication Committee in the intention-to-treat (ITT) population. Safety was assessed in all patients who received protocol treatment. The trial is registered with ClinicalTrials.gov, NCT02851407. Findings: Between Jan 11, 2017, and Oct 20, 2020, 372 patients (172 [46%] women and 200 [54%] men; median age 14·0 years [IQR 4·0–41·0] were randomly assigned to the defibrotide prophylaxis group (n=190) or best supportive care group (n=182; ITT population). On the basis of recommendations from the Independent Data Monitoring Committee following completion of the planned interim analysis in the first 280 recruited patients on April 29, 2020, enrolment was prematurel
- Published
- 2023
20. Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system
- Author
-
Cani, A., Parenzan, C. T., Frasson, C., Rampazzo, E., Scarparo, P., Francescato, S., Caicci, F., Barbieri, V., Rosato, A., Cesaro, S., Zecca, M., Micalizzi, C., Sainati, L., Pigazzi, M., Biffi, A., Buldini, B., Locatelli, Franco, Persano, L., Masetti, R., te Kronnie, G., Bresolin, S., Locatelli F. (ORCID:0000-0002-7976-3654), Cani, A., Parenzan, C. T., Frasson, C., Rampazzo, E., Scarparo, P., Francescato, S., Caicci, F., Barbieri, V., Rosato, A., Cesaro, S., Zecca, M., Micalizzi, C., Sainati, L., Pigazzi, M., Biffi, A., Buldini, B., Locatelli, Franco, Persano, L., Masetti, R., te Kronnie, G., Bresolin, S., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO-derived cells' migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.
- Published
- 2023
21. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
- Author
-
Van Weelderen, R. E., Klein, K., Harrison, C. J., Jiang, Y., Abrahamsson, J., Arad-Cohen, N., Bart-Delabesse, E., Buldini, B., De Moerloose, B., Dworzak, M. N., Elitzur, S., Fernandez Navarro, J. M., Gerbing, R. B., Goemans, B. F., De Groot-Kruseman, H. A., Guest, E., Ha, S. -Y., Hasle, H., Kelaidi, C., Lapillonne, H., Leverger, G., Locatelli, Franco, Masetti, R., Miyamura, T., Noren-Nystrom, U., Polychronopoulou, S., Rasche, M., Rubnitz, J. E., Stary, J., Tierens, A., Tomizawa, D., Zwaan, C. M., Kaspers, G. J. L., Locatelli F. (ORCID:0000-0002-7976-3654), Van Weelderen, R. E., Klein, K., Harrison, C. J., Jiang, Y., Abrahamsson, J., Arad-Cohen, N., Bart-Delabesse, E., Buldini, B., De Moerloose, B., Dworzak, M. N., Elitzur, S., Fernandez Navarro, J. M., Gerbing, R. B., Goemans, B. F., De Groot-Kruseman, H. A., Guest, E., Ha, S. -Y., Hasle, H., Kelaidi, C., Lapillonne, H., Leverger, G., Locatelli, Franco, Masetti, R., Miyamura, T., Noren-Nystrom, U., Polychronopoulou, S., Rasche, M., Rubnitz, J. E., Stary, J., Tierens, A., Tomizawa, D., Zwaan, C. M., Kaspers, G. J. L., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
PURPOSEA previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease.METHODSA total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (%0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS).RESULTSThe high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P <.0001), CIR (59.7% v 35.2%; P <.0001), and OS (49.2% v 70.5%; P <.0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P <.0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P <.0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P =.016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P =.00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS.CONCLUSIONEOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are nee
- Published
- 2023
22. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
- Author
-
Masetti, R., Leardini, D., Muratore, E., Fabbrini, M., D'Amico, F., Zama, D., Baccelli, F., Gottardi, F., Belotti, T., Ussowicz, M., Fraczkiewicz, J., Cesaro, S., Zecca, M., Merli, P., Candela, M., Pession, A., Locatelli, Franco, Prete, A., Brigidi, P., Turroni, S., Locatelli F. (ORCID:0000-0002-7976-3654), Masetti, R., Leardini, D., Muratore, E., Fabbrini, M., D'Amico, F., Zama, D., Baccelli, F., Gottardi, F., Belotti, T., Ussowicz, M., Fraczkiewicz, J., Cesaro, S., Zecca, M., Merli, P., Candela, M., Pession, A., Locatelli, Franco, Prete, A., Brigidi, P., Turroni, S., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The correlation existing between gut microbiota diversity and survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has so far been studied in adults. Pediatric studies question whether this association applies to children as well. Stool samples from a multicenter cohort of 90 pediatric allo-HSCT recipients were analyzed using 16S ribosomal RNA amplicon sequencing to profile the gut microbiota and estimate diversity with the Shannon index. A global-to-local networking approach was used to characterize the ecological structure of the gut microbiota. Patients were stratified into higher- and lower-diversity groups at 2 time points: before transplantation and at neutrophil engraftment. The higher-diversity group before transplantation exhibited a higher probability of overall survival (88.9% ± 5.7% standard error [SE] vs 62.7% ± 8.2% SE; P = .011) and lower incidence of grade 2 to 4 and grade 3 to 4 acute graft-versus-host disease (aGVHD). No significant difference in relapse-free survival was observed between the 2 groups (80.0% ± 6.0% SE vs 55.4% ± 10.8% SE; P = .091). The higher-diversity group was characterized by higher relative abundances of potentially health-related microbial families, such as Ruminococcaceae and Oscillospiraceae. In contrast, the lower-diversity group showed an overabundance of Enterococcaceae and Enterobacteriaceae. Network analysis detected short-chain fatty acid producers, such as Blautia, Faecalibacterium, Roseburia, and Bacteroides, as keystones in the higher-diversity group. Enterococcus, Escherichia-Shigella, and Enterobacter were instead the keystones detected in the lower-diversity group. These results indicate that gut microbiota diversity and composition before transplantation correlate with survival and with the likelihood of developing aGVHD.
- Published
- 2023
23. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome
- Author
-
Vivarelli, M., Colucci, M., Algeri, M., Zotta, F., Emma, F., L'Erario, I., Busutti, M., Rota, S., Capelli, C., Introna, M., Todeschini, M., Casiraghi, F., Perna, A., Peracchi, T., De Salvo, A., Rubis, N., Locatelli, Franco, Remuzzi, G., Ruggenenti, P., Locatelli F. (ORCID:0000-0002-7976-3654), Vivarelli, M., Colucci, M., Algeri, M., Zotta, F., Emma, F., L'Erario, I., Busutti, M., Rota, S., Capelli, C., Introna, M., Todeschini, M., Casiraghi, F., Perna, A., Peracchi, T., De Salvo, A., Rubis, N., Locatelli, Franco, Remuzzi, G., Ruggenenti, P., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
BACKGROUNDSevere forms of idiopathic nephrotic syndrome (INS) require prolonged immunosuppressive therapies and repeated courses of high-dose glucocorticoids. Mesenchymal stromal cells (MSCs) have promising immunomodulatory properties that may be employed therapeutically to reduce patient exposure to medications and their side effects.METHODSWe performed a phase I open-label trial assessing safety and feasibility of autologous bone marrow-derived MSCs (BM-MSCs) in children and young adults with severe forms of steroid-dependent nephrotic syndrome. Following autologous BM-MSC preparation and infusion, oral immunosuppression was tapered. Safety, efficacy, and immunomodulatory effects in vivo were monitored for 12 months.RESULTSSixteen patients (10 children, 6 adults) were treated. Adverse events were limited and not related to BM-MSC infusions. All patients relapsed during follow-up, but in the 10 treated children, time to first relapse was delayed (P = 0.02) and number of relapses was reduced (P = 0.002) after BM-MSC infusion, compared with the previous 12 months. Cumulative prednisone dose was also reduced at 12 months compared with baseline (P < 0.05). No treatment benefit was observed in adults.In children, despite tapering of immunosuppression, clinical benefit was mirrored by a significant reduction in total CD19+, mature, and memory B cells and an increase in regulatory T cells in vivo up to 3-6 months following BM-MSC infusionCONCLUSIONTreatment with autologous BM-MSCs is feasible and safely reduces relapses and immunosuppression at 12 months in children with severe steroid-dependent INS. Immunomodulatory studies suggest that repeating MSC infusions at 3-6 months may sustain benefit.TRIAL REGISTRATIONEudraCT 2016-004804-77.FUNDINGAIFA Ricerca Indipendente 2016-02364623.
- Published
- 2023
24. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL
- Author
-
del Bufalo, F., Becilli, M., Rosignoli, C., De Angelis, B., Algeri, M., Hanssens, L., Gunetti, M., Iacovelli, S., Li Pira, G., Girolami, E., Leone, G., Lazzaro, S., Bertaina, V., Sinibaldi, M., Di Cecca, S., Iaffaldano, L., Kunkele, A., Boccieri, E., Del Baldo, G., Pagliara, D., Merli, P., Carta, R., Quintarelli, C., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), del Bufalo, F., Becilli, M., Rosignoli, C., De Angelis, B., Algeri, M., Hanssens, L., Gunetti, M., Iacovelli, S., Li Pira, G., Girolami, E., Leone, G., Lazzaro, S., Bertaina, V., Sinibaldi, M., Di Cecca, S., Iaffaldano, L., Kunkele, A., Boccieri, E., Del Baldo, G., Pagliara, D., Merli, P., Carta, R., Quintarelli, C., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Autologous CD19-directed chimeric antigen receptor (CAR)-T cells have shown unprecedented efficacy in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, patients either relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or displaying profound lymphopenia and/or rapidly progressing disease often cannot access autologous products. These hurdles may be overcome by allogeneic, donor-derived CAR-T cells. We tested donor-derived T cells transduced with a second-generation (4.1BB) CD19-directed CAR for treatment of patients with BCP-ALL in a hospital-exemption setting. Two constructs were tested: a retroviral construct incorporating the suicide gene inducible caspase-9 (CD19-CAR–Retro_ALLO) first and then a lentiviral construct and an automated, Prodigy-based manufacturing process (CD19-CAR–Lenti_ALLO). Thirteen children/young adults received ALLO–CAR-T cells between March 2021 and October 2022. Doses ranged between 1.0 × 106 and 3.0 × 106 CAR-T cells per kg. The toxicity profile was comparable with that of autologous CAR-T cells, characterized mainly by cytopenia, cytokine release syndrome (maximum grade 1), and grade 2 immune-effector cell–associated neurotoxicity syndrome. One case of acute graft-versus-host disease (GVHD) occurred and was rapidly controlled with steroids and ruxolitinib. None of the other patients, including 3 given ALLO–CAR-T cells from an HLA-haploidentical donor, experienced GVHD. Two patients received ALLO–CAR-T cells before HSCT and showed a significant expansion of CAR-T cells without any sign of GVHD. All patients obtained complete remission (CR) with absence of minimal residual disease in the bone marrow. With a median follow-up of 12 months (range, 5-21), 8 of 13 patients maintained CR. Allogeneic anti-CD19 CAR-T cells can effectively treat highly refractory BCP-ALL relapsing after allo-HSCT without showing increased toxicity as compared with autologous CAR-T cells.
- Published
- 2023
25. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply
- Author
-
Quintarelli, C., Del Bufalo, F., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Quintarelli, C., Del Bufalo, F., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
To the Editor: Del Bufalo et al. (April 6 issue)(1) describe the treatment of patients with relapsed or refractory pediatric neuroblastoma with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 and express the inducible capsase 9 suicide gene (GD2-CART01). Among the children who had a relapse after this treatment, the authors did not observe reexpansion of T cells, and the GD2 antigen was still expressed on tumor cells. We were surprised by the surface-marker analysis of the GD2-CAR T cells that led the authors to conclude that these cells were not exhausted. The data show that the . . .
- Published
- 2023
26. Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties
- Author
-
Cseh, A., Galimard, J. -E., de la Fuente, J., Isgro, A., Zecca, M., Garwer, B., Biffi, A., Aljurf, M., Sundin, M., Belendez, C., Locatelli, Franco, Balduzzi, A., Lawson, S., Sengeloev, H., Ifversen, M., Saccardi, R., Wynn, R., Lankester, A. C., Corbacioglu, S., Peters, C., Locatelli F. (ORCID:0000-0002-7976-3654), Cseh, A., Galimard, J. -E., de la Fuente, J., Isgro, A., Zecca, M., Garwer, B., Biffi, A., Aljurf, M., Sundin, M., Belendez, C., Locatelli, Franco, Balduzzi, A., Lawson, S., Sengeloev, H., Ifversen, M., Saccardi, R., Wynn, R., Lankester, A. C., Corbacioglu, S., Peters, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
How important is choice of conditioning regimen in allogeneic haematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD)? We compared HSCT outcomes by conditioning regimen in paediatric patients with SCD from the EBMT registry. In 2010-2020, 251 patients aged <18 years underwent a first matched sibling donor (MSD) HSCT with conditioning based on busulfan-fludarabine (bu-flu; n = 89) or treosulfan-fludarabine (treo-flu; n = 162). In the bu-flu and treo-flu groups, 51.7% and 99.4% of patients, respectively, received thiotepa. Median follow-up was 2.7 years. Two-year overall survival (OS) was 98.7% (95% confidence interval [CI]: 90.9-99.8) with bu-flu and 99.3% (95% CI: 95.2-99.9) with treo-flu (p = 0.63). Grade III-IV acute graft-versus-host disease (GVHD) at 100 days was 2.4% (95% CI: 0.4-7.5) and 0.6% (0.1%-3.2%) for bu-flu and treo-flu respectively (p = 0.25). The 2-year incidence of extensive chronic GVHD was 1.5% (95% CI: 0.1-7.3) with bu-flu and 8.0% (95% CI: 4.1-13.3) with treo-flu (p = 0.057). These multinational data confirm the excellent curative capacity of MSD HSCT with myeloablative conditioning. Both conditioning regimens yielded excellent OS, low rates of acute and chronic GVHD, and low rates of graft failure.
- Published
- 2023
27. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
- Author
-
Locatelli, Franco, Zugmaier, G., Mergen, N., Bader, P., Jeha, S., Schlegel, P. -G., Bourquin, J. -P., Handgretinger, R., Brethon, B., Rossig, C., Kormany, W. N., Viswagnachar, P., Chen-Santel, C., Locatelli F. (ORCID:0000-0002-7976-3654), Locatelli, Franco, Zugmaier, G., Mergen, N., Bader, P., Jeha, S., Schlegel, P. -G., Bourquin, J. -P., Handgretinger, R., Brethon, B., Rossig, C., Kormany, W. N., Viswagnachar, P., Chen-Santel, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (.28 days and, 18 years) with CD191 relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) received up to 5 cycles of blinatumomab by continuous infusion (cycle: 4 weeks on/2 weeks off). The primary end point was incidence of adverse events. Secondary end points included complete response (CR) and measurable residual disease (MRD) response within the first 2 cycles and relapse-free survival (RFS), overall survival (OS), and allogeneic hematopoietic stem cell transplant (alloHSCT) after treatment. At final data cutoff (10 January 2020), 110 patients were enrolled (median age, 8.5 years; 88% had ≥5% baseline blasts). A low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%) was reported; no blinatumomab-related fatal adverse events were recorded. The probability of response was not affected by the presence of cytogenetic/molecular abnormalities. Median OS was 14.6 months (95% confidence interval [CI]: 11.0-not estimable) and was significantly better for MRD responders vs MRD nonresponders (not estimable vs 9.3; hazard ratio, 0.18; 95% CI: 0.08-0.39). Of patients achieving CR after 2 cycles, 73.5% (95% CI: 61.4%- 83.5%) proceeded to alloHSCT. One-year OS probability was higher for patients who received alloHSCT vs without alloHSCT after blinatumomab (87% vs 29%). These findings support the use of blinatumomab as a safe and efficacious treatment of pediatric R/R B-ALL. This trial was registered at www.clinicaltrials.gov as #NCT02187354.
- Published
- 2022
28. Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement
- Author
-
Di Nardo, M., Ahmad, A. H., Merli, P., Zinter, M. S., Lehman, L. E., Rowan, C. M., Steiner, M. E., Hingorani, S., Angelo, J. R., Abdel-Azim, H., Khazal, S. J., Shoberu, B., Mcarthur, J., Bajwa, R., Ghafoor, S., Shah, S. H., Sandhu, H., Moody, K., Brown, B. D., Mireles, M. E., Steppan, D., Olson, T., Raman, L., Bridges, B., Duncan, C. N., Choi, S. W., Swinford, R., Paden, M., Fortenberry, J. D., Peek, G., Tissieres, P., De Luca, D., Locatelli, Franco, Corbacioglu, S., Kneyber, M., Franceschini, A., Nadel, S., Kumpf, M., Loreti, A., Wosten-Van Asperen, R., Gawronski, O., Brierley, J., Maclaren, G., Mahadeo, K. M., Locatelli F. (ORCID:0000-0002-7976-3654), Di Nardo, M., Ahmad, A. H., Merli, P., Zinter, M. S., Lehman, L. E., Rowan, C. M., Steiner, M. E., Hingorani, S., Angelo, J. R., Abdel-Azim, H., Khazal, S. J., Shoberu, B., Mcarthur, J., Bajwa, R., Ghafoor, S., Shah, S. H., Sandhu, H., Moody, K., Brown, B. D., Mireles, M. E., Steppan, D., Olson, T., Raman, L., Bridges, B., Duncan, C. N., Choi, S. W., Swinford, R., Paden, M., Fortenberry, J. D., Peek, G., Tissieres, P., De Luca, D., Locatelli, Franco, Corbacioglu, S., Kneyber, M., Franceschini, A., Nadel, S., Kumpf, M., Loreti, A., Wosten-Van Asperen, R., Gawronski, O., Brierley, J., Maclaren, G., Mahadeo, K. M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.
- Published
- 2022
29. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency
- Author
-
Quinti, I., Locatelli, Franco, Carsetti, R., Locatelli F. (ORCID:0000-0002-7976-3654), Quinti, I., Locatelli, Franco, Carsetti, R., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
CVID patients have an increased susceptibility to vaccine-preventable infections. The question on the potential benefits of immunization of CVID patients against SARS-CoV-2 offered the possibility to analyze the defective mechanisms of immune responses to a novel antigen. In CVID, as in immunocompetent subjects, the role of B and T cells is different between infected and vaccinated individuals. Upon vaccination, variable anti-Spike IgG responses have been found in different CVID cohorts. Immunization with two doses of mRNA vaccine did not generate Spike-specific classical memory B cells (MBCs) but atypical memory B cells (ATM) with low binding capacity to Spike protein. Spike-specific T-cells responses were also induced in CVID patients with a variable frequency, differently from specific T cells produced after multiple exposures to viral antigens following influenza virus immunization and infection. The immune response elicited by SARS-CoV-2 infection was enhanced by subsequent immunization underlying the need to immunize convalescent COVID-19 CVID patients after recovery. In particular, immunization after SARS-Cov-2 infection generated Spike-specific classical memory B cells (MBCs) with low binding capacity to Spike protein and Spike-specific antibodies in a high percentage of CVID patients. The search for a strategy to elicit an adequate immune response post-vaccination in CVID patients is necessary. Since reinfection with SARS-CoV-2 has been documented, at present SARS-CoV-2 positive CVID patients might benefit from new preventing strategy based on administration of anti-SARS-CoV-2 monoclonal antibodies.
- Published
- 2022
30. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
- Author
-
Vinti, L., Pagliara, D., Buffardi, S., Di Ruscio, V., Stocchi, F., Mariggio, E., Parasole, R., Di Matteo, A., Petruzziello, F., Paganelli, V., De Vito, R., Del Bufalo, F., Strocchio, L., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Vinti, L., Pagliara, D., Buffardi, S., Di Ruscio, V., Stocchi, F., Mariggio, E., Parasole, R., Di Matteo, A., Petruzziello, F., Paganelli, V., De Vito, R., Del Bufalo, F., Strocchio, L., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
- Published
- 2022
31. Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants
- Author
-
Baccelli, F., Leardini, D., Muratore, E., Messelodi, D., Bertuccio, S. N., Chiriaco, M., Cancrini, C., Conti, F., Castagnetti, F., Pedace, L., Pession, A., Yoshimi, A., Niemeyer, C., Tartaglia, M., Locatelli, Franco, Masetti, R., Locatelli F. (ORCID:0000-0002-7976-3654), Baccelli, F., Leardini, D., Muratore, E., Messelodi, D., Bertuccio, S. N., Chiriaco, M., Cancrini, C., Conti, F., Castagnetti, F., Pedace, L., Pession, A., Yoshimi, A., Niemeyer, C., Tartaglia, M., Locatelli, Franco, Masetti, R., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: CBL syndrome is a RASopathy caused by heterozygous germline mutations of the Casitas B-lineage lymphoma (CBL) gene. It is characterized by heterogeneous clinical phenotype, including developmental delay, facial dysmorphisms, cardiovascular malformations and an increased risk of cancer development, particularly juvenile myelomonocytic leukemia (JMML). Although the clinical phenotype has been progressively defined in recent years, immunological manifestations have not been well elucidated to date. Methods: We studied the genetic, immunological, coagulative, and clinical profile of a family with CBL syndrome that came to our observation after the diagnosis of JMML, with homozygous CBL mutation, in one of the members. Results: Variant analysis revealed the co-occurrence of CBL heterozygous mutation (c.1141 T > C) and SH2B3 mutation (c.1697G > A) in two other members. Patients carrying both mutations showed an ALPS-like phenotype characterized by lymphoproliferation, cytopenia, increased double-negative T-cells, impaired Fas-mediated lymphocyte apoptosis, altered cell death in PBMC and low TRECs expression. A coagulative work-up was also performed and showed the presence of subclinical coagulative alterations in patients carrying both mutations. Conclusion: In the reported family, we described immune dysregulation, as part of the clinical spectrum of CBL mutation with the co-occurrence of SH2B3.
- Published
- 2022
32. The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic
- Author
-
Agrati, C., Carsetti, R., Bordoni, V., Sacchi, A., Quintarelli, C., Locatelli, Franco, Ippolito, G., Capobianchi, M. R., Locatelli F. (ORCID:0000-0002-7976-3654), Agrati, C., Carsetti, R., Bordoni, V., Sacchi, A., Quintarelli, C., Locatelli, Franco, Ippolito, G., Capobianchi, M. R., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The COVID-19 pandemic has represented an unprecedented challenge for the humanity, and scientists around the world provided a huge effort to elucidate critical aspects in the fight against the pathogen, useful in designing public health strategies, vaccines and therapeutic approaches. One of the first pieces of evidence characterizing the SARS-CoV-2 infection has been its breadth of clinical presentation, ranging from asymptomatic to severe/deadly disease, and the indication of the key role played by the immune response in influencing disease severity. This review is aimed at summarizing what the SARS-CoV-2 infection taught us about the immune response, highlighting its features of a double-edged sword mediating both protective and pathogenic processes. We will discuss the protective role of soluble and cellular innate immunity and the detrimental power of a hyper-inflammation-shaped immune response, resulting in tissue injury and immunothrombotic events. We will review the importance of B- and T-cell immunity in reducing the clinical severity and their ability to cross-recognize viral variants.
- Published
- 2022
33. Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry
- Author
-
Petrilli, L. L., Fuoco, C., Palma, A., Pasquini, L., Pericoli, G., Grabovska, Y., Mackay, A., Rossi, S., Carcaboso, A. M., Carai, A., Mastronuzzi, A., Jones, C., Cesareni, G., Locatelli, Franco, Vinci, M., Locatelli F. (ORCID:0000-0002-7976-3654), Petrilli, L. L., Fuoco, C., Palma, A., Pasquini, L., Pericoli, G., Grabovska, Y., Mackay, A., Rossi, S., Carcaboso, A. M., Carai, A., Mastronuzzi, A., Jones, C., Cesareni, G., Locatelli, Franco, Vinci, M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Paediatric-type diffuse high-grade gliomas (PDHGG) are aggressive tumors affecting children and young adults, with no effective treatment. These highly heterogeneous malignancies arise in different sites of the Central Nervous System (CNS), carrying distinctive molecular alterations and clinical outcomes (inter-tumor heterogeneity). Moreover, deep cellular and molecular profiling studies highlighted the coexistence of genetically and phenotypically different subpopulations within the same tumor mass (intra-tumor heterogeneity). Despite the recent advances made in the field, the marked heterogeneity of PDHGGs still impedes the development of effective targeted therapies and the identification of suitable biomarkers. In order to fill the existing gap, we used mass cytometry to dissect PDHGG inter- and intra-heterogeneity. This is one of the most advanced technologies of the “-omics” era that, using antibodies conjugated to heavy metals, allows the simultaneous measurement of more than 40 markers at single-cell level. To this end, we analyzed eight PDHGG patient-derived cell lines from different locational and molecular subgroups. By using a panel of 15 antibodies, directly conjugated to metals or specifically customized to detect important histone variants, significant differences were highlighted in the expression of the considered antigens. The single-cell multiparametric approach realized has deepened our understanding of PDHGG, confirming a high degree of intra- and inter-tumoral heterogeneity and identifying some antigens that could represent useful biomarkers for the specific PDHGG locational or molecular subgroups.
- Published
- 2022
34. Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia
- Author
-
Merli, P., Guzzo, I., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Merli, P., Guzzo, I., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
no abstract
- Published
- 2022
35. Clinical, Immunological, and Molecular Variability of RAG Deficiency: A Retrospective Analysis of 22 RAG Patients
- Author
-
Cifaldi, C., Rivalta, B., Amodio, D., Mattia, A., Pacillo, L., Di Cesare, S., Chiriaco, M., Ursu, G. M., Cotugno, N., Giancotta, C., Manno, E. C., Santilli, V., Zangari, P., Federica, G., Palumbo, G., Merli, P., Palma, P., Rossi, P., Di Matteo, G., Locatelli, Franco, Finocchi, A., Cancrini, C., Locatelli F. (ORCID:0000-0002-7976-3654), Cifaldi, C., Rivalta, B., Amodio, D., Mattia, A., Pacillo, L., Di Cesare, S., Chiriaco, M., Ursu, G. M., Cotugno, N., Giancotta, C., Manno, E. C., Santilli, V., Zangari, P., Federica, G., Palumbo, G., Merli, P., Palma, P., Rossi, P., Di Matteo, G., Locatelli, Franco, Finocchi, A., Cancrini, C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Purpose: We described clinical, immunological, and molecular characterization within a cohort of 22 RAG patients focused on the possible correlation between clinical and genetic data. Methods: Immunological and genetic features were investigated by multiparametric flow cytometry and by Sanger or next generation sequencing (NGS) as appropriate. Results: Patients represented a broad spectrum of RAG deficiencies: SCID, OS, LS/AS, and CID. Three novel mutations in RAG1 gene and one in RAG2 were reported. The primary symptom at presentation was infections (81.8%). Infections and autoimmunity occurred together in the majority of cases (63.6%). Fifteen out of 22 (68.2%) patients presented autoimmune or inflammatory manifestations. Five patients experienced severe autoimmune cytopenia refractory to different lines of therapy. Total lymphocytes count was reduced or almost lacking in SCID group and higher in OS patients. B lymphocytes were variably detected in LS/AS and CID groups. Eighteen patients underwent HSCT permitting definitive control of autoimmune/hyperinflammatory manifestations in twelve of them (80%). Conclusion: We reinforce the notion that different clinical phenotype can be found in patients with identical mutations even within the same family. Infections may influence genotype–phenotype correlation and function as trigger for immune dysregulation or autoimmune manifestations. Severe and early autoimmune refractory cytopenia is frequent and could be the first symptom of onset. Prompt recognition of RAG deficiency in patients with early onset of autoimmune/hyperinflammatory manifestations could contribute to the choice of a timely and specific treatment preventing the onset of other complications.
- Published
- 2022
36. Case Report: Trichosporon japonicum Fungemia in a Pediatric Patient With Refractory Acute B Cell Lymphoblastic Leukemia
- Author
-
Albitar-Nehme, S., Agosta, M., Kowalska, A. H., Mancinelli, L., Onori, M., Lucignano, B., Mattana, G., Quagliarella, F., Cefalo, M. G., Merli, P., Locatelli, Franco, Perno, C. F., Bernaschi, P., Locatelli F. (ORCID:0000-0002-7976-3654), Albitar-Nehme, S., Agosta, M., Kowalska, A. H., Mancinelli, L., Onori, M., Lucignano, B., Mattana, G., Quagliarella, F., Cefalo, M. G., Merli, P., Locatelli, Franco, Perno, C. F., Bernaschi, P., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Trichosporon japonicum is a very rare opportunistic yeast causing fungal disease in humans, especially in immunocompromised hosts. Here, we describe a new case of T. japonicum isolated from the blood of a pyrexial pediatric patient with refractory acute B cell lymphoblastic leukemia and acute respiratory distress. Prompt diagnosis through early clinical suspicion and appropriate molecular microbiology analysis allowed the yeast to be accurately identified at species level. Subsequent drug susceptibility testing and focused antifungal treatment with voriconazole and amphotericin B led to a complete clinical and mycological resolution of the infection, which represents the second successful case of T. japonicum bloodstream infection described in literature to date.
- Published
- 2022
37. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
- Author
-
Albert, M. H., Slatter, M. A., Gennery, A. R., Gungor, T., Bakunina, K., Markovitch, B., Hazelaar, S., Sirait, T., Courteille, V., Aiuti, A., Aleinikova, O. V., Balashov, D., Bernardo, M. E., Bodova, I., Bruno, B., Cavazzana, M., Chiesa, R., Fischer, A., Hauck, F., Ifversen, M., Kalwak, K., Klein, C., Kulagin, A., Kupesiz, A., Kuskonmaz, B., Lindemans, C. A., Locatelli, Franco, Lum, S. H., Maschan, A., Meisel, R., Moshous, D., Porta, F., Sauer, M. G., Sedlacek, P., Schulz, A., Suarez, F., Vallee, T. C., Winiarski, J. H., Zecca, M., Neven, B., Veys, P., Lankester, A. C., Locatelli F. (ORCID:0000-0002-7976-3654), Albert, M. H., Slatter, M. A., Gennery, A. R., Gungor, T., Bakunina, K., Markovitch, B., Hazelaar, S., Sirait, T., Courteille, V., Aiuti, A., Aleinikova, O. V., Balashov, D., Bernardo, M. E., Bodova, I., Bruno, B., Cavazzana, M., Chiesa, R., Fischer, A., Hauck, F., Ifversen, M., Kalwak, K., Klein, C., Kulagin, A., Kupesiz, A., Kuskonmaz, B., Lindemans, C. A., Locatelli, Franco, Lum, S. H., Maschan, A., Meisel, R., Moshous, D., Porta, F., Sauer, M. G., Sedlacek, P., Schulz, A., Suarez, F., Vallee, T. C., Winiarski, J. H., Zecca, M., Neven, B., Veys, P., Lankester, A. C., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged <5 years at HSCT had a significantly better overall survival. The overall cumulative incidences of grade III to IV acute GVHD and extensive/moderate/severe chronic GVHD were 6.6% and 2.1%, respectively. Patients receiving treosulfan-based conditioning had a higher incidence of graft failure and mixed donor chimerism and more frequently underwent secondary procedures (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.
- Published
- 2022
38. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study
- Author
-
Locatelli, Franco, Maschan, A., Boissel, N., Strocchio, L., Alam, N., Pezzani, I., Brescianini, A., Kreuzbauer, G., Baruchel, A., Locatelli F. (ORCID:0000-0002-7976-3654), Locatelli, Franco, Maschan, A., Boissel, N., Strocchio, L., Alam, N., Pezzani, I., Brescianini, A., Kreuzbauer, G., Baruchel, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Prior to regulatory approval of blinatumomab in pediatric patients with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph− BCP-ALL), blinatumomab was made available via an expanded access program (EAP). Procedure: This retrospective observational study included patients receiving blinatumomab in the EAP between January 1, 2014 and June 30, 2017 who were followed until death, entry into a clinical trial, end of follow-up, or end of the study period (December 31, 2017), whichever occurred first. Results: Among 113 children enrolled, 72 were diagnosed with R/R Ph− BCP-ALL and 41 were minimal residual disease positive (MRD+, either Ph− or Ph+). In the R/R group, 38 (53%) patients achieved hematological response within two cycles. Of these, 19 (50%) proceeded to hematopoietic stem cell transplantation (HSCT) without bridging myelosuppressive therapy. Of 36 patients in the R/R group evaluable for MRD, 30 (83%) had an MRD response. In the R/R group, median relapse-free survival was 5.4 months and median overall survival (OS) was 8.2 months. Of 36 patients in the MRD+ group who were evaluable for MRD after two cycles, 27 (75%) had an MRD response. Overall, 24 (59%) of the MRD+ patients proceeded to HSCT without other bridging therapy. Median disease-free survival was 13.6 months; median OS was not reached. Conclusions: In this real-world pediatric cohort, blinatumomab was effective within two cycles. Over half of patients with R/R Ph− BCP-ALL achieved hematological response and most achieved MRD response in the MRD+ group, confirming the efficacy of blinatumomab in pediatric trials.
- Published
- 2022
39. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study
- Author
-
Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., Locatelli F. (ORCID:0000-0002-7976-3654), Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Importance: Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials. Objective: To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses. Design: A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients. Setting: National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL) Participants: People consenting and included in the VAX4FRAIL trial. Exposure: A series of three doses of COVID-19 mRNA vaccination from the same manufacturer. Main outcome(s) and measure(s): Evaluation of a self-assessment questionnaire addressing a predefined list of eight symptoms on a five-item Likert scale. Symptoms were classified as severe if the patient rated them as severe or overwhelming. Results: Among 320 VAX4FRAIL participants diagnosed/treated for hematological malignancies (N=105; 32.8%), solid tumors (N=48; 15.0%), immune-rheumatological diseases (N=60; 18.8%), neurological diseases (N=107; 33.4%), and receiving the booster dose, 70.3% reported at least one loco-regional or systemic reactions. Adverse events were mostly mild or moderate, none being life-threatening. Only six of the 320 (1.9%) patients had their treatment postponed due to the vaccine. The safety profile of the booster compared to previously administered two doses showed a stable prevalence of patients with one or more adverse events (73.5%, 79.7% and 73.9% respectively), and a slightly increment of patients with one or more severe adverse events (13.4%, 13.9% and 19.2% respectively). Conclusions and relevance: The booster of the mRNA COVID-19 vaccine was safely adminis
- Published
- 2022
40. Glucocorticoids inhibit human hematopoietic stem cell differentiation toward a common ILC precursor
- Author
-
Quatrini, L., Tumino, N., Besi, F., Ciancaglini, C., Galaverna, F., Grasso, A. G., Merli, P., Locatelli, Franco, Vacca, P., Moretta, L., Locatelli F. (ORCID:0000-0002-7976-3654), Quatrini, L., Tumino, N., Besi, F., Ciancaglini, C., Galaverna, F., Grasso, A. G., Merli, P., Locatelli, Franco, Vacca, P., Moretta, L., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Innate lymphoid cells (ILCs) comprise cytotoxic natural killer (NK) cells and helper ILCs (hILCs). Human hILC development is less characterized as compared with that of NK cells, although all ILCs are developmentally related. It has been reported that the immunosuppressive drugs glucocorticoids (GCs) regulate ILC function, but whether they control ILC differentiation from hematopoietic stem cells (HSCs) is unknown. Objectives: This study sought to analyze the effect of GCs on ILC development from HSCs. Methods: This study exploited an in vitro system to generate and expand from peripheral blood HSCs a multipotent CD56+ ILC precursor able to differentiate into NK cells, ILC1s, and ILC3s. We also analyzed ex vivo, at different time points, the peripheral blood of recipients of allogeneic HSC transplantation who were or were not treated with GCs and compared ILC subset reconstitution. Results: In vitro, GCs favor the generation of NK cells from myeloid precursors, while they strongly impair lymphoid development. In support of these data, recipients of HSC transplantation who had been treated with GCs display a lower number of circulating hILCs, including the ILC precursor (ILCP) previously identified as a systemic substrate for tissue ILC differentiation. Conclusions: GCs impair the development of the CD117+ ILCP from CD34+ HSCs, while they do not affect the further steps of ILCP differentiation toward NK cells and hILC subsets. This reflects an association of GC treatment with a marked reduction of circulating hILCs in the recipients of HSC transplantation.
- Published
- 2022
41. Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population
- Author
-
Lucignano, B., Cento, V., Agosta, M., Ambrogi, F., Albitar-Nehme, S., Mancinelli, L., Mattana, G., Onori, M., Galaverna, F., Di Chiara, L., Fragasso, T., Bianchi, R., Tortora, F., Auriti, C., Dotta, A., Cecchetti, C., Perdichizzi, S., Raponi, M., Muda, A. O., Molteni, S. N., Villani, A., Locatelli, Franco, Perno, C. F., Bernaschi, P., Locatelli F. (ORCID:0000-0002-7976-3654), Lucignano, B., Cento, V., Agosta, M., Ambrogi, F., Albitar-Nehme, S., Mancinelli, L., Mattana, G., Onori, M., Galaverna, F., Di Chiara, L., Fragasso, T., Bianchi, R., Tortora, F., Auriti, C., Dotta, A., Cecchetti, C., Perdichizzi, S., Raponi, M., Muda, A. O., Molteni, S. N., Villani, A., Locatelli, Franco, Perno, C. F., Bernaschi, P., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Children are prone to bloodstream infections (BSIs), the rapid and accurate diagnosis of which is an unmet clinical need. The T2MR technology is a direct molecular assay for identification of BSI pathogens, which can help to overcome the limits of blood culture (BC) such as diagnostic accuracy, blood volumes required, and turnaround time. We analyzed results obtained with the T2Bacteria (648) and T2Candida (106) panels in pediatric patients of the Bambino Gesù Children's Hospital between May 2018 and September 2020 in order to evaluate the performance of the T2Dx instrument with respect to BC. T2Bacteria and T2Candida panels showed 84.2% and 100% sensitivity with 85.9% and 94.1% specificity, respectively. The sensitivity and specificity of the T2Bacteria panel increased to 94.9% and 98.7%, respectively, when BC was negative but other laboratory data supported the molecular result. T2Bacteria sensitivity was 100% with blood volumes ,2 mL in neonates and infants. T2Bacteria and T2Candida provided definitive microorganism identification in a mean time of 4.4 and 3.7 h, respectively, versus 65.7 and 125.5 h for BCs (P , 0.001). T2 panels rapidly and accurately enable a diagnosis of a pediatric BSI, even in children under 1 year of age and for very small blood volumes. These findings support their clinical use in life-threatening pediatric infections, where the time to diagnosis is of utmost importance, in order to improve survival and minimize the long-term sequalae of sepsis. The T2 technology could be further developed to include more bacteria and fungi species that are involved in the etiology of sepsis.
- Published
- 2022
42. Identification of the novel HLA-B allele, HLA-B*44:532 by next-generation sequencing
- Author
-
Galluccio, T., Locatelli, Franco, Pinto, R. M., Testa, G., Andreani, M., Locatelli F. (ORCID:0000-0002-7976-3654), Galluccio, T., Locatelli, Franco, Pinto, R. M., Testa, G., Andreani, M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The novel HLA-B*44:532 allele differs from HLA-B*44:02:01:01 by one nucleotide substitution in Exon 3.
- Published
- 2022
43. ADAR2 Protein Is Associated with Overall Survival in GBM Patients and Its Decrease Triggers the Anchorage-Independent Cell Growth Signature
- Author
-
Cesarini, V., Silvestris, D. A., Galeano, F., Tassinari, V., Martini, M., Locatelli, Franco, Gallo, A., Locatelli F. (ORCID:0000-0002-7976-3654), Cesarini, V., Silvestris, D. A., Galeano, F., Tassinari, V., Martini, M., Locatelli, Franco, Gallo, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Epitranscriptomic mechanisms, such as A-to-I RNA editing mediated by ADAR deaminases, contribute to cancer heterogeneity and patients’ stratification. ADAR enzymes can change the sequence, structure, and expression of several RNAs, affecting cancer cell behavior. In glioblastoma, an overall decrease in ADAR2 RNA level/activity has been reported. However, no data on ADAR2 protein levels in GBM patient tissues are available; and most data are based on ADARs overexpression experiments. Methods: We performed IHC analysis on GBM tissues and correlated ADAR2 levels and patients’ overall survival. We silenced ADAR2 in GBM cells, studied cell behavior, and performed a gene expression/editing analysis. Results: GBM tissues do not all show a low/no ADAR2 level, as expected by previous studies. Although, different amounts of ADAR2 protein were observed in different patients, with a low level correlating with a poor patient outcome. Indeed, reducing the endogenous ADAR2 protein in GBM cells promotes cell proliferation and migration and changes the cell’s program to an anchorage-independent growth mode. In addition, deep-seq data and bioinformatics analysis indicated multiple RNAs are differently expressed/edited upon siADAR2. Conclusion: ADAR2 protein is an important deaminase in GBM and its amount correlates with patient prognosis.
- Published
- 2022
44. mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
- Author
-
Lupo-Stanghellini, M. T., Di Cosimo, S., Costantini, M., Monti, S., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., Apolone, G., Ciliberto, G., Baldanti, F., Morrone, A., Sinno, V., Locatelli, Franco, Notari, S., Turola, E., Giannarelli, D., Silvestris, N., Locatelli F. (ORCID:0000-0002-7976-3654), Lupo-Stanghellini, M. T., Di Cosimo, S., Costantini, M., Monti, S., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., Apolone, G., Ciliberto, G., Baldanti, F., Morrone, A., Sinno, V., Locatelli, Franco, Notari, S., Turola, E., Giannarelli, D., Silvestris, N., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine adverse events and disease worsening was one of the reasons for vaccine hesitancy. Herein, we report the safety profile of the prospective, multicenter, national VAX4FRAIL study (NCT04848493) to evaluate vaccines in a large trans-disease cohort of patients with solid or hematological malignancies and neurological and rheumatological diseases. Methods: Between March 3 and September 2, 2021, 566 patients were evaluable for safety endpoint: 105 received the mRNA-1273 vaccine and 461 the BNT162b2 vaccine. Frail patients were defined per protocol as patients under treatment with hematological malignancies (n = 131), solid tumors (n = 191), immune-rheumatological diseases (n = 86), and neurological diseases (n = 158), including multiple sclerosis and generalized myasthenia. The impact of the vaccination on the health status of patients was assessed through a questionnaire focused on the first week after each vaccine dose. Results: The most frequently reported moderate–severe adverse events were pain at the injection site (60.3% after the first dose, 55.4% after the second), fatigue (30.1%–41.7%), bone pain (27.4%–27.2%), and headache (11.8%–18.9%). Risk factors associated with the occurrence of severe symptoms after vaccine administration were identified through a multivariate logistic regression analysis: age was associated with severe fever presentation (younger patients vs. middle-aged vs. older ones), female individuals presented a higher probability of severe pain at the injection site, fatigue, headache, and bone pain; and the mRNA-1237 vaccine was associated with a higher probability of severe pain at the injection site and fever. After the first dose, patients presenting a se
- Published
- 2022
45. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia
- Author
-
Burke, M. J., Ziegler, D. S., Bautista, F., Attarbaschi, A., Gore, L., Locatelli, Franco, M. O'Brien, M., Pauly, M., Kormany, W. N., Tian, S., Morris, C. L., Baruchel, A., Locatelli F. (ORCID:0000-0002-7976-3654), Burke, M. J., Ziegler, D. S., Bautista, F., Attarbaschi, A., Gore, L., Locatelli, Franco, M. O'Brien, M., Pauly, M., Kormany, W. N., Tian, S., Morris, C. L., Baruchel, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in childhood. Survival for patients following relapse remains poor, and achieving complete remission (CR) after relapse is the first critical step to cure. Carfilzomib is a proteasome inhibitor with an acceptable safety profile and clinical activity in adults with multiple myeloma but has not been assessed in children. The primary objective of this phase 1b study was to assess the safety and tolerability of carfilzomib combined with vincristine, dexamethasone, asparaginase, and daunorubicin (VXLD) in children with relapsed and/or refractory ALL. Methods: Patients aged 1–21 years (n = 24) received 4-week induction therapy with carfilzomib at dose levels of 27 mg/m2 (n = 3), 36 mg/m2 (n = 7), 45 mg/m2 (n = 4), and 56 mg/m2 (n = 10) in combination with VXLD. Patients achieving stable disease were offered further consolidation chemotherapy. Analyses were based on the safety evaluable population. Results: Following dose escalation of carfilzomib, the recommended phase 2 carfilzomib dose was identified as 56 mg/m2. Grade ≥3 hematological adverse events were common (83%, 20/24 patients), and serious treatment-emergent adverse events occurred in 58% (14/24) of patients. At the end of induction, CR/CR with incomplete platelet recovery (CRp)/CR with incomplete blood count recovery (CRi) was identified in 50% of patients (n = 12/24). By the end of consolidation, cumulative CR/CRp/CRi was identified in 58% of patients (n = 14/24). Conclusion: These data support the use of carfilzomib in pediatric patients with relapsed and/or refractory ALL.
- Published
- 2022
46. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
- Author
-
Buchmann, S., Schrappe, M., Baruchel, A., Biondi, A., Borowitz, M., Campbell, M., Cario, G., Cazzaniga, G., Escherich, G., Harrison, C. J., Heyman, M., Hunger, S. P., Kiss, C., Liu, H. -C., Locatelli, Franco, Loh, M. L., Manabe, A., Mann, G., Pieters, R., Pui, C. -H., Rives, S., Schmiegelow, K., Silverman, L. B., Stary, J., Vora, A., Brown, P., Locatelli F. (ORCID:0000-0002-7976-3654), Buchmann, S., Schrappe, M., Baruchel, A., Biondi, A., Borowitz, M., Campbell, M., Cario, G., Cazzaniga, G., Escherich, G., Harrison, C. J., Heyman, M., Hunger, S. P., Kiss, C., Liu, H. -C., Locatelli, Franco, Loh, M. L., Manabe, A., Mann, G., Pieters, R., Pui, C. -H., Rives, S., Schmiegelow, K., Silverman, L. B., Stary, J., Vora, A., Brown, P., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Comparison of treatment strategies in de novo pediatric acute lymphoblastic leukemia (ALL) requires standardized measures of efficacy. Key parameters that define disease-related events, including complete remission (CR), treatment failure (TF; not achieving CR), and relapse (loss of CR) require an updated consensus incorporating modern diagnostics. We collected the definitions of CR, TF, and relapse from recent and current pediatric clinical trials for the treatment of ALL, including the key components of response evaluation (timing, anatomic sites, detection methods, and thresholds) and found significant heterogeneity, most notably in the definition of TF. Representatives of the major international ALL clinical trial groups convened to establish consensus definitions. CR should be defined at a time point no earlier than at the end of induction and should include the reduction of blasts below a specific threshold in bone marrow and extramedullary sites, incorporating minimal residual disease (MRD) techniques for marrow evaluations. TF should be defined as failure to achieve CR by a prespecified time point in therapy. Relapse can only be defined in patients who have achieved CR and must include a specific threshold of leukemic cells in the bone marrow confirmed by MRD, the detection of central nervous system leukemia, or documentation of extramedullary disease. Definitions of TF and relapse should harmonize with eligibility criteria for clinical trials in relapsed/refractory ALL. These consensus definitions will enhance the ability to compare outcomes across pediatric ALL trials and facilitate development of future international collaborative trials.
- Published
- 2022
47. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
- Author
-
Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hematopoietic stem cell transplantation (HSCT) is a curative post-remission treatment in patients with acute myeloid leukemia (AML), but relapse after transplant is still a challenging event. In recent year, several studies have investigated the molecular minimal residual disease (qPCR-MRD) as a predictor of relapse, but the lack of standardized protocols, cut-offs, and timepoints, especially in the pediatric setting, has prevented its use in several settings, including before HSCT. Here, we propose the first collaborative retrospective I-BFM-AML study assessing qPCR-MRD values in pretransplant bone marrow samples of 112 patients with a diagnosis of AML harboring t(8;21)(q22; q22)RUNX1::RUNX1T1, or inv(16)(p13q22)CBFB::MYH11, or t(9;11)(p21;q23)KMT2A::MLLT3, or FLT3-ITD genetic markers. We calculated an ROC cut-off of 2.1 × 10−4 that revealed significantly increased OS (83.7% versus 57.1%) and EFS (80.2% versus 52.9%) for those patients with lower qPCR-MRD values. Then, we partitioned patients into three qPCR-MRD groups by combining two different thresholds, 2.1 × 10−4 and one lower cut-off of 1 × 10−2, and stratified patients into low-, intermediate-, and high-risk groups. We found that the 5-year OS (83.7%, 68.6%, and 39.2%, respectively) and relapse-free survival (89.2%, 73.9%, and 67.9%, respectively) were significantly different independent of the genetic lesion, conditioning regimen, donor, and stem cell source. These data support the PCR-based approach playing a clinical relevance in AML transplant management.
- Published
- 2022
48. Evidence of pediatric sepsis caused by a drug resistant Lactococcus garvieae contaminated platelet concentrate
- Author
-
Colagrossi, L., Costabile, V., Scutari, R., Agosta, M., Onori, M., Mancinelli, L., Lucignano, B., Onetti Muda, A., Del Baldo, G., Mastronuzzi, A., Locatelli, Franco, Trua, G., Montanari, M., Alteri, C., Bernaschi, P., Perno, C. F., Locatelli F. (ORCID:0000-0002-7976-3654), Colagrossi, L., Costabile, V., Scutari, R., Agosta, M., Onori, M., Mancinelli, L., Lucignano, B., Onetti Muda, A., Del Baldo, G., Mastronuzzi, A., Locatelli, Franco, Trua, G., Montanari, M., Alteri, C., Bernaschi, P., Perno, C. F., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Owing to an increasing number of infections in adults, Lactococcus (L.) garvieae has gained recognition as an emerging human pathogen, causing bacteraemia and septicaemia. In September 2020, four paediatric onco-hematologic patients received a platelet concentrate from the same adult donor at Bambino Gesù Children’s Hospital IRCCS, Rome. Three of four patients experienced L. garvieae sepsis one day after transfusion. The L. garvieae pediatric isolates and the donor’s platelet concentrates were retrospectively collected for whole-genome sequencing and shot-gun metagenomics, respectively (Illumina HiSeq). By de novo assembly of the L. garvieae genomes, we found that all three pediatric isolates shared a 99.9% identity and were characterized by 440 common SNPs. Plasmid pUC11C (conferring virulence properties) and the temperate prophage Plg-Tb25 were detected in all three strains. Core SNP genome-based maximum likelihood and Bayesian trees confirmed their phylogenetic common origin and revealed their relationship with L. garvieae strains affecting cows and humans (bootstrap values >100 and posterior probabilities = 1.00). Bacterial reads obtained by the donor’s platelet concentrate have been profiled with MetaPhlAn2 (v.2.7.5); among these, 29.9% belonged to Firmicutes, and 5.16% to Streptococcaceae (>97% identity with L. garvieae), confirming the presence of L. garvieae in the platelet concentrate transfusion. These data showed three episodes of sepsis for the first time due to a transfusion-associated transmission of L. garvieae in three pediatric hospitalized hematology patients. This highlights the importance to implement the screening of platelet components with new human-defined pathogens for ensuring the safety of blood supply, and more broadly, for the surveillance of emerging pathogens.
- Published
- 2022
49. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis
- Author
-
Masetti, R., Muratore, E., Gori, D., Prete, A., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Masetti, R., Muratore, E., Gori, D., Prete, A., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Identification of pediatric patients with acute myeloid leukemia (AML) candidates to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) is still a matter of debate. Currently, transplantation is reserved to patients considered at high risk of relapse based on cytogenetics, molecular biology, and minimal residual disease (MRD) assessment. However, no randomized clinical trial exists in the literature comparing transplantation with other types of consolidation therapy. Here, we provide an up-to-date meta-analysis of studies comparing allo-HSCT in CR1 with chemotherapy alone as a post-remission treatment in high-risk pediatric AML. The literature search strategy identified 10 cohorts from 9 studies performing as-treated analysis. The quantitative synthesis showed improved overall survival (OS) (relative risk, 1.15; 95% confidence interval [CI], 1.06–1.24; P = 0.0006) and disease-free survival (relative risk, 1.31; 95% CI, 1.17–1.47; P = 0.0001) in the allo-HSCT group, with increased relapse rate in the chemotherapy group (relative risk, 1.26; 95% CI, 1.07–1.49; P = 0.006). Sensitivity analysis including prospective studies alone and excluding studies that reported the comparison only on intermediate-risk patients confirmed the benefit of allo-HSCT on OS. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
- Published
- 2022
50. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
- Author
-
Pianigiani, G., Gagliardi, A., Mezzasoma, F., Rocchio, F., Tini, V., Bigerna, B., Sportoletti, P., Caruso, S., Marra, A., Peruzzi, S., Petito, E., Spinozzi, G., Shacham, S., Landesman, Y., Quintarelli, C., Gresele, P., Locatelli, Franco, Martelli, M. P., Falini, B., Brunetti, L., Locatelli F. (ORCID:0000-0002-7976-3654), Pianigiani, G., Gagliardi, A., Mezzasoma, F., Rocchio, F., Tini, V., Bigerna, B., Sportoletti, P., Caruso, S., Marra, A., Peruzzi, S., Petito, E., Spinozzi, G., Shacham, S., Landesman, Y., Quintarelli, C., Gresele, P., Locatelli, Franco, Martelli, M. P., Falini, B., Brunetti, L., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NPM1 is the most frequently mutated gene in adults with acute myeloid leukemia (AML). The interaction between mutant NPM1 (NPM1c) and exportin-1 (XPO1) causes aberrant cytoplasmic dislocation of NPM1c and promotes the high expression of homeobox (HOX) genes, which is critical for maintaining the leukemic state of NPM1-mutated cells. Although there is a rationale for using XPO1 inhibitors in NPM1-mutated AML, selinexor administered once or twice per week did not translate into clinical benefit in patients with NPM1 mutations. Here, we show that this dosing strategy results in only a temporary disruption of the XPO1-NPM1c interaction, limiting the efficacy of selinexor. Because the second-generation XPO1 inhibitor eltanexor can be administered more frequently, we tested the antileukemic activity of prolonged XPO1 inhibition in NPM1-mutated AML models. Eltanexor caused irreversible HOX downregulation, induced terminal AML differentiation, and prolonged the survival of leukemic mice. This study provides essential information for the appropriate design of clinical trials with XPO1 inhibitors in NPM1-mutated AML.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.